Clinical and genetic profile of actinic prurigo in Thai patients
Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand
Chulalongkorn University · NCT07055009
This project will test whether specific HLA genetic types are linked to how actinic prurigo looks and responds to treatment in Thai people with the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 47 (estimated) |
| Sex | All |
| Sponsor | Chulalongkorn University (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Bangkok) |
| Trial ID | NCT07055009 on ClinicalTrials.gov |
What this trial studies
This cross-sectional comparative project enrolls Thai patients with actinic prurigo and age-matched healthy controls to compare clinical features and genetic markers. Participants undergo full skin examinations, targeted long-read HLA sequencing, RNA extraction, and blood testing including Epstein–Barr virus viral load. The study collects clinical presentation and treatment-response data to look for associations with HLA alleles and other genetic signatures. Recruitment is coordinated across multiple collaborating hospitals with standardized diagnostic criteria and data collection methods.
Who should consider this trial
Good fit: Ideal participants are Thai-ethnicity adults diagnosed with actinic prurigo who are mentally competent, can communicate and read Thai, and can attend the participating hospitals.
Not a fit: People with other photodermatoses, non-Thai ancestry, an elevated EBV viral load, or whose only abnormality is a low UVB minimal erythema dose are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, the work could help clinicians link specific HLA types to disease patterns and treatment response, enabling more personalized diagnosis and management for Thai patients.
How similar studies have performed: HLA associations with actinic prurigo and related photodermatoses have been reported in other populations, but comprehensive clinico-genetic data specific to Thai patients remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Thai ethnicity * Diagnosed with Actinic Prurigo (AP) according to the diagnostic criteria defined for this study * Mentally competent, able to communicate, and able to read Thai. * Participants receiving Thalidomide treatment must use two simultaneous methods of contraception, starting at least 4 weeks prior to initiating the medication and continuing throughout the treatment period and for at least 4 weeks after discontinuation. Exclusion Criteria: * History and physical examination findings suggestive of other photodermatoses such as Lupus erythematosus, Porphyria, or Polymorphous Light Eruption, among others. * Elevated Epstein-Barr Virus (EBV) viral load detected in blood testing (EBV viral load will be tested in all participants). * Low Minimal Erythema Dose (MED) to UVB radiation as the only abnormal finding.
Where this trial is running
Bangkok
- Faculty of Medicine Chulalongkorn University — Bangkok, Thailand (RECRUITING)
Study contacts
- Study coordinator: Einapak Boontaveeyuwat, MD
- Email: einapak.b@chula.ac.th
- Phone: +66922995700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Actinic Prurigo, Actinic prurigo, subtype actinic prurigo, HLA typing, genetic